Biotech Startups

1 investor

Sentieon develops optimized bioinformatics algorithms for genomic data processing, particularly for precision medicine applications. The company specializes in variant calling and other secondary analysis tools that process next-generation sequencing data.

1 investor

Sentinal4D develops interpretable machine learning tools for analyzing 3D and 4D cell morphology in drug discovery and mechanistic biology. PointMIL is a framework that classifies static 3D cell point clouds while providing point-level explanations of model predictions, enabling scientists to see where on the cell surface the model finds evidence for biological conclusions.

1 investor

A biopharmaceutical company developing novel medicines for rare diseases, serving patients and caregivers from early detection through therapeutic intervention.

1 investor

Seonix develops a genetic risk score to identify individuals at elevated risk of glaucoma, serving eye health professionals, patients, and researchers. The company uses large-scale genetic datasets and advanced techniques for clinical risk prediction to help prevent vision loss.

1 investor

Septest develops rapid point-of-need diagnostic tests for detecting infections and inflammation, including its multi-marker TRISEP test aimed at pre-hospital and community triage. The tools are intended for frontline healthcare professionals to speed sepsis detection and reduce antimicrobial resistance, with a focus on accessibility including in low- and middle-income countries.

1 investor

SeqCenter provides DNA sequencing services with an emphasis on data security and biosecurity for research organizations. The company operates U.S.-based infrastructure with secure data handling, chain-of-custody tracking, and encrypted delivery methods.

1 investor

Seqera is a bioinformatics platform that centralizes scientific data, orchestrates pipelines, and provides governance, auditability, and reproducibility across on-premises and cloud environments (AWS, GCP, Azure). Built by the team behind the Nextflow workflow engine, it serves bioinformaticians, lab scientists, and R&D teams working on genomics and AI-based drug discovery.

1 investor

Sequoia Vaccines develops vaccine treatments for infectious diseases, with a focus on prevention of recurrent urinary tract infections. The company operates in the biotechnology industry with expertise in vaccine development, clinical trials, and manufacturing.

1 investor

Serán is a contract development and manufacturing organization (CDMO) that provides drug formulation, development, and manufacturing services to pharmaceutical companies. The company specializes in process engineering, scaleup, and commercial manufacturing of solid dosage forms and advanced pharmaceutical technologies.

1 investor

Serapha Bio is a biotechnology company. It has announced a merger agreement with Boundless Bio alongside a $230 million concurrent private placement.

1 investor

SERB is a pharmaceutical company specializing in rare diseases and emergency medicine, with a portfolio of 70+ medicines including antidotes for chemical, biological, radiological and nuclear threats. The company serves hospitals, healthcare systems, first responders, and patients with rare conditions in oncology, neurology, and metabolic disorders across 100+ countries.

1 investor

SERDA therapeutics is developing a prescription enzyme-based product for therapeutic debridement, using a proteolytic enzyme to selectively digest and remove necrotic tissue and eschar from wounds. It targets burn injuries and chronic wounds such as open leg and diabetic foot ulcers.

1 investor

Serenatis Bio develops small-molecule drugs targeting glutamate and dopamine pathways to treat obsessive-compulsive disorder, a mental health condition with limited effective therapeutic options. The company's pipeline includes three novel candidates designed to work faster and with fewer side effects than existing medications.

1 investor

Serentrix is a biotech company developing targeted small-molecule therapies for pain relief that aim to avoid the addiction risks associated with existing painkillers.

1 investor

Serina Therapeutics is a clinical-stage biotechnology company developing its POZ Platform, a polymer technology ("POZylation") that modifies proven small molecule drugs to enable controlled, sustained release with fewer side effects. Its lead candidate, SER-252 (POZ-apomorphine), targets advanced Parkinson's disease, and the platform is also applied to CNS indications and RNA medicines.

1 investor

This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms. The domain belongs to Seroba Life Sciences, but the visible content only covers an Azafaros clinical trial announcement rather than describing the site owner itself.

1 investor

Serotiny designs cell therapies using custom software and lab techniques that allow it to design and test up to 10,000 therapeutic genes at once, aiming to speed up the discovery of treatments for cancers such as multiple myeloma, prostate cancer and lung cancer. The San Francisco-based company works upstream in the cell and gene therapy discovery process and was acquired by Johnson & Johnson.

1 investor

Seroxo is a biotech company developing technology in the areas of immunology, cancer, and infectious disease, supported by a clinical advisory board of specialists. The company is associated with the University of Oxford research community.

1 investor

SetBone Medical develops solutions for spinal care and orthopedic applications. The company is advised by leading spine surgeons and orthopedic specialists.

1 investor

SEYSARA is a prescription medication with a patient co-pay assistance program (Almirall Advantage) that offers savings on retail and network pharmacy purchases. The page is a manufacturer's patient savings/co-pay support site for people with private health insurance.

1 investor

Shaddari offers an AI system that predicts whether existing vaccines can neutralize a newly isolated virus variant using only its genetic code, returning results quickly instead of through weeks of lab testing. It is aimed at public and private labs working in precision medicine.

1 investor

Shanton Pharma is a clinical-stage biotech company developing drugs for gout, hyperuricemia, and pruritus. It focuses on researching and commercializing therapies for these conditions to serve patients and medical communities.

1 investor

ShanX Medtech develops a diagnostic platform that identifies bacterial infections and determines antibiotic susceptibility from patient samples within approximately one hour. The system serves clinicians in hospital microbiology labs and point-of-care settings, providing targeted treatment guidance based on individual patient needs.

1 investor